Merrimack Pharmaceuticals
MACK
#8368
Rank
โ‚ฌ0.19 B
Marketcap
13,00ย โ‚ฌ
Share price
0.00%
Change (1 day)
-6.61%
Change (1 year)

Earnings for Merrimack Pharmaceuticals (MACK)

Earnings in 2024 (TTM): -โ‚ฌ2.09 Million

According to Merrimack Pharmaceuticals's latest financial reports the company's current earnings are N/A. In 2023 the company made an earning of -โ‚ฌ1.87 Million a decrease over its 2022 earnings that were of -โ‚ฌ1.87 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Merrimack Pharmaceuticals from 2010 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -โ‚ฌ2.09 Million11.61%
2023 -โ‚ฌ1.87 Million0.09%
2022 -โ‚ฌ1.87 Million-16.9%
2021 -โ‚ฌ2.25 Million-49.89%
2020 -โ‚ฌ4.49 Million-75.39%
2019 -โ‚ฌ18.22 Million-68.58%
2018 -โ‚ฌ57.99 Million-19.4%
2017 -โ‚ฌ71.94 Million-36.46%
2016 -โ‚ฌ0.12 Billion2.54%
2015 -โ‚ฌ0.12 Billion96.78%
2014 -โ‚ฌ56.12 Million-45.44%
2013 -โ‚ฌ0.11 Billion
2010 -โ‚ฌ39.89 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
โ‚ฌ7.81 B-402,944.62%๐Ÿ‡ซ๐Ÿ‡ท France
AVEO Oncology
AVEO
-โ‚ฌ24.95 Million 1,185.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Geron
GERN
-โ‚ฌ39.45 Million 1,932.93%๐Ÿ‡บ๐Ÿ‡ธ USA
Clovis Oncology
CLVS
-โ‚ฌ0.19 Billion 9,523.90%๐Ÿ‡บ๐Ÿ‡ธ USA
Eterna Therapeutics
ERNA
-โ‚ฌ8.16 Million 320.05%๐Ÿ‡บ๐Ÿ‡ธ USA